Quick Answer
Mineralys Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $172.92 million for the year ending 2025.
- Mineralys Therapeutics, Inc. showed an increase of +51.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Mineralys Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: $138.25 million | Q2 2023: $101.14 million | Q3 2023: $86.30 million | Q1 2024: $90.42 million | Q2 2024: $67.86 million | Q3 2024: $97.27 million | Q1 2025: $165.01 million | Q2 2025: $101.79 million | Q3 2025: $217.60 million.
- Over the full 4 years of available data (2022 to 2025), Mineralys Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 97.2%.
- Historical annual values: Fiscal year 2025: $172.92 million | Fiscal year 2024: $114.09 million | Fiscal year 2023: $49.30 million | Fiscal year 2022: $87.70 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: